All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2021-12-16T14:52:22.000Z

What is the rationale behind step-up dosing of glofitamab in patients with MCL?

By Camilla Rossi
Featured
Tycel Phillips
Dec 16, 2021
Share:

Bookmark this article

During the 63rd ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Tycel Phillips, University of Michigan, Ann Arbor, US. We asked, What is the rationale behind step-up dosing of glofitamab in patients with mantle cell lymphoma (MCL)?

What is the rationale behind step-up dosing of glofitamab in patients with MCL?


He begins by outlining the challenges faced in relapsed/refractory (R/R) MCL, the study aims and design. Phillips notes the promising efficacy of the treatment with high overall and complete response rates. He highlights that further research would investigate the long-term durability of this treatment, and discusses adverse events.

 

More about...
ASH 2021GlofitamabMantle cell lymphomaMantle cell lymphomas

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Parsaclisib, a potent and highly selective next-generation PI3Kδ inhibitor: a summary of data from the three CITADEL trials (203, 204, and 205)

Non-Hodgkin lymphoma (NHL) includes a variety of subtypes and the behavior, treatment, and outcomes...

Jan 14, 2022
Add bookmark

Parsaclisib, a potent and highly selective next-generation PI3Kδ inhibitor: a summary of data from the three CITADEL trials (203, 204, and 205)

Non-Hodgkin lymphoma (NHL) includes a variety of...

Jan 14, 2022
Add bookmark

Phase I study of CD20-TCB, a novel T-cell-engaging bispecific antibody, in R/R NHL

During the 25th Congress of the European Hematology Association (EHA), the Lymphoma Hub spoke to Michael Dickinson, Peter MacCallum Cancer Centre and The Royal...

Jun 16, 2020
Add bookmark

Phase I study of CD20-TCB, a novel T-cell-engaging bispecific antibody, in R/R NHL

During the 25th Congress of the European Hematology Association (EHA), the Lymphoma Hub spoke to Michael Dickinson,...

Jun 16, 2020

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox